2Seventy Bio Inc
NASDAQ:TSVT
Intrinsic Value
2seventy Bio, Inc. operates as cell and gene therapy company. [ Read More ]
The intrinsic value of one TSVT stock under the Base Case scenario is 3.25 USD. Compared to the current market price of 4.63 USD, 2Seventy Bio Inc is Overvalued by 30%.
Valuation Backtest
2Seventy Bio Inc
Run backtest to discover the historical profit from buying and selling TSVT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
2Seventy Bio Inc
Current Assets | 237.8m |
Cash & Short-Term Investments | 217m |
Receivables | 13.4m |
Other Current Assets | 7.4m |
Non-Current Assets | 327.7m |
Long-Term Investments | 4.8m |
PP&E | 278.1m |
Intangibles | 6.6m |
Other Non-Current Assets | 38.1m |
Current Liabilities | 59.8m |
Accounts Payable | 6m |
Accrued Liabilities | 38.3m |
Other Current Liabilities | 15.4m |
Non-Current Liabilities | 250.3m |
Other Non-Current Liabilities | 250.3m |
Earnings Waterfall
2Seventy Bio Inc
Revenue
|
100.4m
USD
|
Cost of Revenue
|
-16.9m
USD
|
Gross Profit
|
83.5m
USD
|
Operating Expenses
|
-300.4m
USD
|
Operating Income
|
-216.9m
USD
|
Other Expenses
|
-632k
USD
|
Net Income
|
-217.6m
USD
|
Free Cash Flow Analysis
2Seventy Bio Inc
What is Free Cash Flow?
TSVT Profitability Score
Profitability Due Diligence
2Seventy Bio Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
2Seventy Bio Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
TSVT Solvency Score
Solvency Due Diligence
2Seventy Bio Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
2Seventy Bio Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TSVT Price Targets Summary
2Seventy Bio Inc
According to Wall Street analysts, the average 1-year price target for TSVT is 11.22 USD with a low forecast of 5.05 USD and a high forecast of 26.25 USD.
Ownership
TSVT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TSVT Price
2Seventy Bio Inc
Average Annual Return | 14.41% |
Standard Deviation of Annual Returns | 112.63% |
Max Drawdown | -96% |
Market Capitalization | 234.4m USD |
Shares Outstanding | 51 311 100 |
Percentage of Shares Shorted | 13.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
Contact
IPO
Employees
Officers
The intrinsic value of one TSVT stock under the Base Case scenario is 3.25 USD.
Compared to the current market price of 4.63 USD, 2Seventy Bio Inc is Overvalued by 30%.